hepatocellular carcinoma

AstraZeneca’s Imfinzi meets PFS primary endpoint in Phase III HCC trial
AstraZeneca’s Imfinzi meets PFS primary endpoint in Phase III HCC trial
Clinical Trials Arena
AstraZeneca
clinical trials
Imfinzi
hepatocellular carcinoma
Flag link:
Harbour reports results from HCC combo therapy trial
Harbour reports results from HCC combo therapy trial
Clinical Trials Arena
Harbour BioMed
porustobart
HCC
hepatocellular carcinoma
clinlcal trials
Flag link:
Genentech reveals positive results from cancer combo therapy trial
Genentech reveals positive results from cancer combo therapy trial
Clinical Trials Arena
Genentech
Tecentriq
Avastin
liver cancer
hepatocellular carcinoma
Flag link:
Medivir completes initial Phase Ib part of HCC therapy trial
Medivir completes initial Phase Ib part of HCC therapy trial
Clinical Trials Arena
Medvir
fostrox
Lenvima
hepatocellular carcinoma
clinical trials
Flag link:
BeiGene and Novartis Make Late-Stage Progress against Liver Cancer
BeiGene and Novartis Make Late-Stage Progress against Liver Cancer
BioSpace
Novartis
BeiGene
hepatocellular carcinoma
liver cancer
clinical trials
Flag link:
Omega Gets FDA Nod to Start First-Ever Epigenomic Controller Trial
Omega Gets FDA Nod to Start First-Ever Epigenomic Controller Trial
BioSpace
Omega Therapeutics
hepatocellular carcinoma
OTX-2002
epigenomic controllers
clinical trials
Flag link:
FDA bars the door — for now — against Merck’s star cancer drug after Roche beat them to the punch
FDA bars the door — for now — against Merck’s star cancer drug after Roche beat them to the punch
Endpoints
Merck
FDA
complete response letter
Keytruda
Eisaid
Lenvima
hepatocellular carcinoma
Roche
Flag link:
Bristol Myers Squibb snags new liver cancer nod for Opdivo-Yervoy combo
Bristol Myers Squibb snags new liver cancer nod for Opdivo-Yervoy combo
Fierce Pharma
Bristol-Myers Squibb
Opdivo
Yervoy
FDA
liver cancer
hepatocellular carcinoma
Flag link:
AstraZeneca’s Combination Treatment for HCC Snags Orphan Drug Designation
AstraZeneca’s Combination Treatment for HCC Snags Orphan Drug Designation
BioSpace
AstraZeneca
Imfinzi
orphan drugs
FDA
hepatocellular carcinoma
Flag link:
Lilly gets fifth use for Cyramza with FDA liver cancer nod
Lilly gets fifth use for Cyramza with FDA liver cancer nod
Pharmaforum
Eli Lilly
Cyramza
FDA
liver cancer
hepatocellular carcinoma
Flag link:
RNAi Therapeutics Focused Sirnaomics Closes $47 Million Series C Round
RNAi Therapeutics Focused Sirnaomics Closes $47 Million Series C Round
CP Wire
Sriaomics
STP705
cholangiocarcinoma
hepatocellular carcinoma
RNAi
Flag link:
RNAi Therapeutics Focused Sirnaomics Closes $47 Million Series C Round
Sriaomics
STP705
cholangiocarcinoma
hepatocellular carcinoma
Flag link:
AZ begins liver cancer immunotherapy tie-up with AVEO
AZ begins liver cancer immunotherapy tie-up with AVEO
Pharmaforum
AstraZeneca
Aveo Oncology
cancer immunotherapy
Imfinzi
Fotivda
hepatocellular carcinoma
Flag link:
Merck gets FDA okay for Keytruda as liver cancer therapy
Merck gets FDA okay for Keytruda as liver cancer therapy
Pharmaforum
Merck
Keytruda
FDA
hepatocellular carcinoma
liver cancer
Flag link:
Exelixis and Ipsen Announce Positive CHMP Opinion for Cabometyx in Previously Treated Hepatocellular Carcinoma
Exelixis and Ipsen Announce Positive CHMP Opinion for Cabometyx in Previously Treated Hepatocellular Carcinoma
CP WIre
Exelixis
Ipsen
Cabometyx
hepatocellular carcinoma
Flag link:
Exelixis and Ipsen Announce Positive CHMP Opinion for Cabometyx in Previously Treated Hepatocellular Carcinoma
Exelixis
Ipsen
Cabometyx
hepatocellular carcinoma
Flag link:
Eisai and Merck Announce China Approval of Lenvima for Treatment of Unresectable Hepatocellular Carcinoma
Eisai
Merck
Lenvima
liver cancer
hepatocellular carcinoma
Flag link:
European Commission Approves New First Line Treatment for Advanced or Unresectable Hepatocellular Carcinoma – First in a Decade
European Commission Approves New First Line Treatment for Advanced or Unresectable Hepatocellular Carcinoma – First in a Decade
CP WIre
Eisai
Merck
Lenvima
hepatocellular carcinoma
Europe
Flag link:
European Commission Approves New First Line Treatment for Advanced or Unresectable Hepatocellular Carcinoma – First in a Decade
Eisai
Merck
Lenvima
hepatocellular carcinoma
Flag link:
Eisai-Merck partnership picks up first-line Lenvima approval
Eisai-Merck partnership picks up first-line Lenvima approval
Biopharma Dive
FDA
Eisai
Merck
Lenvima
hepatocellular carcinoma
Flag link:

Pages